River Global Investors LLP Purchases New Position in Organon & Co. (NYSE:OGN)

River Global Investors LLP bought a new position in shares of Organon & Co. (NYSE:OGN - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 49,406 shares of the company's stock, valued at approximately $712,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Lindbrook Capital LLC lifted its stake in Organon & Co. by 348.3% in the 4th quarter. Lindbrook Capital LLC now owns 1,838 shares of the company's stock valued at $27,000 after buying an additional 1,428 shares in the last quarter. Harvest Fund Management Co. Ltd lifted its stake in shares of Organon & Co. by 495.5% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company's stock worth $28,000 after purchasing an additional 1,333 shares during the period. Headlands Technologies LLC purchased a new position in shares of Organon & Co. during the 3rd quarter worth $35,000. GAMMA Investing LLC purchased a new position in shares of Organon & Co. during the 4th quarter worth $38,000. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Organon & Co. by 97.7% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,246 shares of the company's stock worth $39,000 after purchasing an additional 1,110 shares during the period. Institutional investors and hedge funds own 77.43% of the company's stock.

Insider Buying and Selling

In other Organon & Co. news, insider Kirke Weaver purchased 2,720 shares of the business's stock in a transaction dated Thursday, February 22nd. The shares were bought at an average price of $18.36 per share, with a total value of $49,939.20. Following the completion of the acquisition, the insider now owns 15,181 shares in the company, valued at approximately $278,723.16. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.17% of the company's stock.

Organon & Co. Stock Up 5.5 %

Shares of Organon & Co. stock traded up $1.07 during trading hours on Monday, hitting $20.68. 3,179,735 shares of the company's stock traded hands, compared to its average volume of 2,731,160. The stock has a 50 day simple moving average of $18.19 and a 200-day simple moving average of $15.76. The company has a market cap of $5.32 billion, a PE ratio of 5.02, a PEG ratio of 0.88 and a beta of 0.81. Organon & Co. has a twelve month low of $10.84 and a twelve month high of $24.08.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.14. The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a negative return on equity of 259.73% and a net margin of 16.50%. As a group, equities research analysts predict that Organon & Co. will post 4.1 EPS for the current year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 13th. Investors of record on Monday, May 13th will be paid a $0.28 dividend. The ex-dividend date of this dividend is Friday, May 10th. This represents a $1.12 dividend on an annualized basis and a yield of 5.42%. Organon & Co.'s dividend payout ratio (DPR) is 27.38%.

Analysts Set New Price Targets

Several brokerages recently weighed in on OGN. Piper Sandler increased their target price on Organon & Co. from $22.00 to $24.00 and gave the stock an "overweight" rating in a research report on Monday, April 29th. The Goldman Sachs Group increased their price target on Organon & Co. from $18.00 to $20.00 and gave the company a "neutral" rating in a report on Friday.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.